

Asia Pacific Point of Care TB And Drug-Resistant TB Testing Market Size, Share & Trends Analysis Report By Test (Molecular Diagnostics, Immunoassays), By End-use (Clinics and Hospitals, Diagnostic Laboratories), By Country, And Segment Forecasts, 2024 - 2030

<https://marketpublishers.com/r/A2ACE08ABE0DEN.html>

Date: September 2024

Pages: 80

Price: US\$ 5,950.00 (Single User License)

ID: A2ACE08ABE0DEN

Abstracts

This report can be delivered to the clients within 3 Business Days

Asia Pacific Point Of Care Diagnostics Market Growth & Trends

The Asia Pacific point of care diagnostics market is expected to reach USD 16.73 billion by 2030, registering a CAGR of 8.4% from 2024 to 2030, according to a new study by Grand View Research, Inc. Growing base of geriatric population and the ability to render immediate results and improve patient care coupled with a rising market penetration of PACS (picture archiving and communication systems) and EMR (electronic medical records) are expected to drive demand over the next six years. Skilled staff shortages, especially pertaining to the field of diagnostics are also expected to accelerate the market penetration rates of point of care (PoC) products, by expediting lab automation processes. Rising demand for home healthcare and other healthcare establishments catering to the elderly population and initiatives undertaken by governments to shorten hospital stays by establishing out-patient care models are also expected to be key market factors.

The rapidly growing use of point of care diagnostic products has introduced a decentralization trend in the overall healthcare industry. Healthcare facilities and patients, in an attempt to attain or cater medical facilities remotely, encourage early

diagnosis and curb costs are now decentralizing their facilities. Furthermore, these trends have also triggered the establishment of remote and stand-alone diagnostic facilities.

Asia Pacific Point Of Care Diagnostics Market Report Highlights

The infectious diseases segment dominated the market with the highest revenue share in 2023 owing to the increasing adoption of point of care diagnostics as a substitute for traditional laboratory testing in infectious diseases applications.

The cancer markers segment is expected to grow at the fastest CAGR over the forecast period from 2024 to 2030. The Asia Pacific region has experienced a notable rise in the prevalence of cancer in recent years.

Glucose testing dominated the market accounting for around 20% of the revenue share in 2023 owing to the high prevalence of diabetes in Asian countries.

The clinics segment held the largest revenue share in 2023. Clinics are essential in providing healthcare services, particularly in remote and underserved areas.

China dominated the Asia Pacific point of care diagnostics market with a revenue share of over 41.5% in 2023. China has the world's largest population and faces notable challenges related to the prevalence of chronic and infectious diseases within its borders resulting in an increasing demand for point-of-care diagnostics.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Test
 - 1.2.2. End Use
 - 1.2.3. Regional scope
 - 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
 - 1.4.5. Details of primary research
 - 1.4.5.1. Data for primary interviews in North America
 - 1.4.5.2. Data for primary interviews in Asia Pacific
 - 1.4.5.3. Data for primary interviews in Asia Pacific
 - 1.4.5.4. Data for primary interviews in Latin America
 - 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Approach 1: Commodity flow approach
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
 - 2.2.1. Test
 - 2.2.2. End Use
 - 2.2.3. Regional outlook

2.3. Competitive Insights

CHAPTER 3. ASIA PACIFIC POC TB AND DRUG-RESISTANT TB TESTING MARKET VARIABLES, TRENDS & SCOPE

3.1. Market Lineage Outlook

- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook

3.2. Market Dynamics

- 3.2.1. Market driver analysis
 - 3.2.1.1. High TB Burden
 - 3.2.1.2. Increased Awareness and Government Initiatives
 - 3.2.1.3. Improving Healthcare Infrastructure
 - 3.2.1.4. Technological Advancements

3.2.2. Market restraint analysis

- 3.2.2.1. High Cost of Advanced Diagnostic Tests
- 3.2.2.2. Regulatory and Approval Challenges

3.3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market Analysis Tools

3.3.1. Industry Analysis – Porter's

- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry

3.3.2. PESTEL Analysis

- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape

CHAPTER 4. ASIA PACIFIC POC TB AND DRUG-RESISTANT TB TESTING MARKET: TEST ESTIMATES & TREND ANALYSIS

4.1. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Dashboard

4.2. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Movement Analysis

4.3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market by Test, Revenue

4.4. Molecular Diagnostics

4.4.1. Molecular Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)

4.5. Immunoassays

4.5.1. Immunoassays market estimates and forecasts 2018 to 2030 (USD Million)

4.6. Culture-based Tests

4.6.1. Culture-based Tests market estimates and forecasts 2018 to 2030 (USD Million)

4.7. Serological Tests

4.7.1. Serological Tests market estimates and forecasts 2018 to 2030 (USD Million)

4.8. Others

4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 5. ASIA PACIFIC POC TB AND DRUG-RESISTANT TB TESTING MARKET: END USE ESTIMATES & TREND ANALYSIS

5.1. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Dashboard

5.2. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Movement Analysis

5.3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market Estimates and Forecasts, By End Use, Revenue (USD Million)

5.4. Clinics and Hospitals

5.4.1. Clinics and Hospitals market estimates and forecasts 2018 to 2030 (USD Million)

5.5. Diagnostic Laboratories

5.5.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)

5.6. Others

5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 6. ASIA PACIFIC POC TB AND DRUG-RESISTANT TB TESTING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY TEST, AND END USE

6.1. Regional Dashboard

6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

6.3. Asia Pacific

6.3.1. Japan

6.3.1.1. Key country dynamics

6.3.1.2. Regulatory framework/ reimbursement structure

6.3.1.3. Competitive scenario

6.3.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)

6.3.2. China

6.3.2.1. Key country dynamics

- 6.3.2.2. Regulatory framework/ reimbursement structure
- 6.3.2.3. Competitive scenario
- 6.3.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.3. India
 - 6.3.3.1. Key country dynamics
 - 6.3.3.2. Regulatory framework/ reimbursement structure
 - 6.3.3.3. Competitive scenario
 - 6.3.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.4. Australia
 - 6.3.4.1. Key country dynamics
 - 6.3.4.2. Regulatory framework/ reimbursement structure
 - 6.3.4.3. Competitive scenario
 - 6.3.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.5. Southeast Asia
 - 6.3.5.1. Key country dynamics
 - 6.3.5.2. Regulatory framework/ reimbursement structure
 - 6.3.5.3. Competitive scenario
 - 6.3.5.4. Southeast Asia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.6. Rest of APAC
 - 6.3.6.1. Key country dynamics
 - 6.3.6.2. Regulatory framework/ reimbursement structure
 - 6.3.6.3. Competitive scenario
 - 6.3.6.4. Rest of APAC market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 7. COMPETITIVE LANDSCAPE

- 7.1. Company/Competition Categorization
- 7.2. Vendor Landscape
 - 7.2.1. List of key distributors and channel partners
 - 7.2.2. Key company market share analysis, 2023
 - 7.2.3. Cepheid (Danaher Corporation)
 - 7.2.3.1. Company overview
 - 7.2.3.2. Financial performance
 - 7.2.3.3. Product benchmarking
 - 7.2.3.4. Strategic initiatives
 - 7.2.4. Molbio Diagnostics
 - 7.2.4.1. Company overview
 - 7.2.4.2. Financial performance
 - 7.2.4.3. Product benchmarking

- 7.2.4.4. Strategic initiatives
- 7.2.5. Abbott Laboratories
 - 7.2.5.1. Company overview
 - 7.2.5.2. Financial performance
 - 7.2.5.3. Product benchmarking
 - 7.2.5.4. Strategic initiatives
- 7.2.6. BD (Becton, Dickinson and Company)
 - 7.2.6.1. Company overview
 - 7.2.6.2. Financial performance
 - 7.2.6.3. Product benchmarking
 - 7.2.6.4. Strategic initiatives
- 7.2.7. Roche Diagnostics
 - 7.2.7.1. Company overview
 - 7.2.7.2. Financial performance
 - 7.2.7.3. Product benchmarking
 - 7.2.7.4. Strategic initiatives
- 7.2.8. Qiagen
 - 7.2.8.1. Company overview
 - 7.2.8.2. Financial performance
 - 7.2.8.3. Product benchmarking
 - 7.2.8.4. Strategic initiatives
- 7.2.9. Lucira Health
 - 7.2.9.1. Company overview
 - 7.2.9.2. Financial performance
 - 7.2.9.3. Product benchmarking
 - 7.2.9.4. Strategic initiatives
- 7.2.10. BioMérieux
 - 7.2.10.1. Company overview
 - 7.2.10.2. Financial performance
 - 7.2.10.3. Product benchmarking
 - 7.2.10.4. Strategic initiatives
- 7.2.11. Thermo Fisher Scientific
 - 7.2.11.1. Company overview
 - 7.2.11.2. Financial performance
 - 7.2.11.3. Product benchmarking
 - 7.2.11.4. Strategic initiatives
- 7.2.12. Fujifilm (Fujifilm Healthcare)
 - 7.2.12.1. Company overview
 - 7.2.12.2. Financial performance

7.2.12.3. Product benchmarking

7.2.12.4. Strategic initiatives

7.2.13. MedMira

7.2.13.1. Company overview

7.2.13.2. Financial performance

7.2.13.3. Product benchmarking

7.2.13.4. Strategic initiatives

7.2.14. SD Biosensor

7.2.14.1. Company overview

7.2.14.2. Financial performance

7.2.14.3. Product benchmarking

7.2.14.4. Strategic initiatives

7.2.15. Trivitron Healthcare

7.2.15.1. Company overview

7.2.15.2. Financial performance

7.2.15.3. Product benchmarking

7.2.15.4. Strategic initiatives

I would like to order

Product name: Asia Pacific Point of Care TB And Drug-Resistant TB Testing Market Size, Share & Trends Analysis Report By Test (Molecular Diagnostics, Immunoassays), By End-use (Clinics and Hospitals, Diagnostic Laboratories), By Country, And Segment Forecasts, 2024 - 2030

Product link: <https://marketpublishers.com/r/A2ACE08ABE0DEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A2ACE08ABE0DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970